{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:07:43Z","timestamp":1780434463060,"version":"3.54.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02435","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T04:32:23Z","timestamp":1540441943000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis"],"prefix":"10.3389","volume":"9","author":[{"given":"Harald","family":"Hegen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette","family":"Walde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Auer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zinganell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Di Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0174005","DOI":"10.1371\/journal.pone.0174005","article-title":"Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study","volume":"12","author":"Hegen","year":"2017","journal-title":"PLoS ONE"},{"key":"B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML Risk Stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurology Neuroimmunol Neuroinflam."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1177\/1352458515599681","article-title":"Anti-JC virus antibody titres increase over time with natalizumab treatment","volume":"21","author":"Raffel","year":"2015","journal-title":"Multiple Scler."},{"key":"B8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J Clin Virol."},{"key":"B9","unstructured":"R: A Language and Environment for Statistical Computing"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult Scler."},{"key":"B12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2055217316630008","DOI":"10.1177\/2055217316630008","article-title":"Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy","volume":"2","author":"Salmen","year":"2016","journal-title":"Multiple Scler. J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jns.2015.11.044","article-title":"JC virus seroprevalence and seroconversion in multiple sclerosis cohort: a Middle-Eastern study","volume":"360","author":"Alroughani","year":"2016","journal-title":"J Neurol Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jns.2016.03.050","article-title":"Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort","volume":"365","author":"Aladro","year":"2016","journal-title":"J Neurol Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/ane.12475","article-title":"Anti-JC virus seroprevalence in a Finnish MS cohort","volume":"133","author":"Kolasa","year":"2016","journal-title":"Acta Neurol Scand."},{"key":"B17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/eci.12721","article-title":"Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort","volume":"47","author":"Dominguez-Mozo","year":"2017","journal-title":"Eur J Clin Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jocn.2017.08.006","article-title":"Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population","volume":"45","author":"Correia","year":"2017","journal-title":"J Clin Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/ene.12988","article-title":"High cumulative JC virus seroconversion rate during long-term use of natalizumab","volume":"23","author":"Vennegoor","year":"2016","journal-title":"Eur J Neurol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02435\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T04:33:16Z","timestamp":1540441996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02435\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2018.02435"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02435","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"article-number":"2435"}}